Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CervoMed Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2026-06-16).
- Action
- entry
- Counterparty
- H.C. Wainwright & Co., LLC
- Effective
- 2026-06-16
Exact text from the filing
On June 16, 2026, the Company entered into an engagement letter, in connection with the Offering (the “Engagement Letter”), with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CervoMed Inc. entered into Securities Purchase Agreement valued at $10.0 million (effective 2026-06-18).
- Action
- entry
- Agreement
- equity purchase
- Value
- $10.0 million
- Effective
- 2026-06-18
Exact text from the filing
On June 18, 2026, CervoMed Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), 2,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $4.00 per Share, for aggregate gross proceeds of $10.0 million, before deducting placement agent fees (as described in greater detail below) and related offering expenses.
View on SEC.gov